Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: New Appointments at Rhinostics, Waters, Congenica

Rhinostics: Cheri Walker

Cheri Walker has been appointed president and CE of Rhinostics, a Cambridge, Massachusetts-based sample collection device firm. Walker has served in management roles at Invitrogen, Qiagen, Charles River Laboratories, Kailos Genetics, and most recently was senior VP of corporate development at Abcam. 


Waters: Sherry Buck, Michael Silveira

Waters announced this week that CFO Sherry Buck will step down as CFO at the end of this month. She has taken a position at a privately held firm, Waters said. Michael Silveira, currently VP and corporate controller at Waters, will assume the role of interim CFO. Waters said it is working with an executive search firm to identify a permanent CFO.


Congenica: Muthu Meyyappan

Congenica has hired Muthu Meyyappan as chief commercial officer. Meyyappan will lead the UK-based company's global sales and marketing efforts from Congenica's US headquarters in Boston. He comes to Congenica from Variantyx, where he also served as CCO. Previous jobs include VP for advanced genomics commercial operations at Qiagen and chief business officer for Biobase, a company Qiagen acquired in 2014.


For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.

 

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.